Teva Moves Forward With LAI Olanzapine Trials
Triggers Payment For Partner MedinCell, After Risperidone Knocked Back By US FDA
Teva is starting Phase III trials for a long-acting injectable formulation of olanzapine, partner MedinCell has revealed. The move comes after the pair were knocked back on their partnered risperidone product earlier this year by the US FDA, with a new expected launch date for that product now also disclosed by the French company.
